Research / HBIO / Fundamental state Inspectable configuration
State dimensions Filing 0001171843-24-004564 General Corporate
Debt relative to revenue RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.debt_to_revenue
154.48% · OPTIONAL · NOT_ENOUGH_HISTORY
Capex intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.capex_revenue_ratio
3.54% · OPTIONAL · NOT_ENOUGH_HISTORY
Operating cash generation RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-3.66% · OPTIONAL · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
-19.69% · CORE · NOT_ENOUGH_HISTORY
Inventory pressure RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
108.80% · OPTIONAL · NOT_ENOUGH_HISTORY
Gross margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.gross_margin
57.23% · CORE · NOT_ENOUGH_HISTORY
Operating margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.operating_margin
-8.96% · CORE · NOT_ENOUGH_HISTORY
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
11.37% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
5.53% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 16 states History building
Sep 30, 2022 0/8 normalized Level 3 Dec 31, 2022 0/8 normalized Level 3 Mar 31, 2023 0/8 normalized Level 3 Jun 30, 2023 0/8 normalized Level 3 Sep 30, 2023 0/9 normalized Level 3 Dec 31, 2023 0/9 normalized Level 3 Mar 31, 2024 0/9 normalized Level 3 Jun 30, 2024 0/9 normalized Level 3 Sep 30, 2024 8/9 normalized Level 3 Dec 31, 2024 8/9 normalized Level 3 Mar 31, 2025 8/9 normalized Level 3 Jun 30, 2025 8/9 normalized Level 3 Sep 30, 2025 9/9 normalized Level 3 Dec 31, 2025 9/9 normalized Level 3 Mar 31, 2026 9/9 normalized Level 3 Jun 30, 2026 9/9 normalized Level 3 Period transition
What moved in the state? Balance Sheet Leverage Increased
Previous 145.28%
Current 154.48%
Delta 9.20% Capex Intensity Increased
Previous 2.63%
Current 3.54%
Delta 0.91% Cash Generation Decreased
Previous 5.72%
Current -3.66%
Delta -9.39% Growth Decreased
Previous -18.23%
Current -19.69%
Delta -1.46% Inventory Pressure Increased
Previous 98.47%
Current 108.80%
Delta 10.34% Margin Decreased
Previous 60.26%
Current 57.23%
Delta -3.04% Profitability Increased
Previous -9.30%
Current -8.96%
Delta 0.34% R And D Intensity Decreased
Previous 11.77%
Current 11.37%
Delta -0.40% Sbc Intensity Increased
Previous 4.28%
Current 5.53%
Delta 1.26% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.